Schizophrenia
Conditions
Keywords
GWAS
Brief summary
This is a GWAS study that aims to identify possible candidate genes associate to schizophrenia by exploring single nucleotide polymorphism (SNP) in a group of schizophrenia, in the Kazakh population. The investigators hypothesize that the careful phenotyping of the subject sand matching with increase the power to find SNP significantly associated with schizophrenia
Detailed description
A genome-wide association study (GWAS) is an approach used in genetics research to associate specific genetic variations with particular diseases. The method involves scanning the genomes from many different people and looking for genetic markers that can be used to predict the presence of a disease. Once such genetic markers are identified, they can be used to understand how genes contribute to the disease and develop better prevention and treatment strategies.
Interventions
GENETICDNA analysis
GWAS
Sponsors
Asfendiyarov Kazakh National Medical University
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* persons of Kazakh nationality having this ethnicity in the 3rd generation * age from 18 to 65 years old; * the dispensary in a psychiatric institution at the place of residence with a diagnosis of Paranoid schizophrenia; * the duration of the disease is at least 1 year (from the moment of taking under dispensary supervision): * absence of severe and chronic somatic diseases; * absence of severe and chronic neurological diseases; * absence of comorbid drug addiction pathology; * signed informed consent to conduct this study
Exclusion criteria
* persons of non-Kazakh nationality and Kazakh nationality, not confirmed until the 3rd generation * age less than 18 years old and over 65 years old; * those who are on dispensary registration in a psychiatric institution at the place of residence with a diagnosis not related to ICD-10 under the heading F20.0 Paranoid schizophrenia; * having a disease duration of less than 1 year (from the moment of taking under dispensary supervision): * having severe and chronic somatic diseases; * having severe and chronic neurological diseases; * having comorbid narcological pathology; * not signed informed consent to conduct this study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| number of SNPs associated with schizophrenia | 1 year | Using GWAS to identify candidate genes associate with schizophrenia |
Countries
Kazakhstan
Outcome results
None listed